Goldman Sachs
LKFT

Goldman Sachs’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Goldman Sachs’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,000
Closed -$1.07M – 6103
2022
Q3 		$1.07M Buy
+25,000
New +$1.28M ﹤0.01% 4456
2022
Q1 		– Sell
-22,500
Closed -$1.24M – 6688
2021
Q4 		$1.24M Sell
22,500
-2,400
-10% -$125K ﹤0.01% 4660
2021
Q3 		$1.31M Buy
+24,900
New +$1.48M ﹤0.01% 4550

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Goldman Sachs's LKFT Position: Q2 2026 in Review

Goldman Sachs increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 25% in Q2 2026, buying an estimated $318K and bringing the position to 56,581 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #4810.

Goldman Sachs first reported a position in LKFT in Q2 2015 and has held it in 44 quarters since. The position peaked at $23.2M in Q4 2015. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • Goldman Sachs held 56,581 shares of Lakefront Biotherapeutics American Depositary Shares worth $1.7M as of Q2 2026.
  • Goldman Sachs bought 11,210 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $318K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4810 holding.
  • Goldman Sachs first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 44 quarters since.
  • Goldman Sachs's Lakefront Biotherapeutics American Depositary Shares position peaked at $23.2M in Q4 2015.
  • 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.